This study characterizes several novel activities of SARS-CoV-2 helicase nsp13, providing valuable insights into potentially new functions of this essential RNA-processing enzyme in the virus life ...
Biomarker data for Sarepta Therapeutics’ RNA programs, licensed from Arrowhead Pharmaceuticals, are “competitive” and “strong,” according to analysts at Jefferies, which projected over $1 billion in ...
Sarepta Therapeutics shares jumped 25% Wednesday morning after the company unveiled promising early clinical data for two medicines that it gained rights to through a deal with Arrowhead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results